Ignacio
Gil Bazo
Investigador hasta 2022
University Hospital of Zurich
Zúrich, SuizaPublicaciones en colaboración con investigadores/as de University Hospital of Zurich (4)
2019
-
Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network
Cancer Research, Vol. 79, Núm. 3, pp. 625-638
-
The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity
Carcinogenesis, Vol. 40, Núm. 2, pp. 324-334
2017
2015
-
Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice
Clinical and Experimental Metastasis, Vol. 32, Núm. 7, pp. 677-687